Skip to main content
. 2021 Oct 30;21:538. doi: 10.1186/s12888-021-03552-0

Table 2.

Corpus callosum volumes (mm3) in CT-SCZ, RT-SCZ, NT-SCZ and HCs

Corpus callosum CT-SCZ, N = 23
Mean ± SD
RT-SCZ, N = 19 Mean ± SD NT-SCZ, N = 23
Mean ± SD
HCs, N = 35
Mean ± SD
F value p value Post-hoc analyses
NT-SCZ
vs. HCs
NT-SCZ
vs. RT-SCZ
NT-SCZ
vs. CT-
SCZ
RT-SCZ
vs. CT-
SCZ
RT-SCZ
vs. HCs
CT-SCZ
vs. HCs
Anterior 916.73 ± 145.59 866.72 ± 155.71 831.76 ± 110.77 845.43 ± 124.69 0.601 0.616 NS NS NS NS NS NS
Mid-anterior 530.28 ± 135.11 590.23 ± 126.91 460.38 ± 76.92 611.49 ± 150.69 6.380 0.001 < 0.001*** 0.024* NS NS NS 0.012*
Central 546.32 ± 152.74 538.48 ± 123.73 490.27 ± 114.93 600.16 ± 139.44 3.318 0.023 0.006** NS NS NS NS NS
Mid-posterior 479.59 ± 96.39 500.46 ± 107.27 454.47 ± 87.86 503.92 ± 78.22 1.287 0.284 NS NS NS NS NS NS
Posterior 942.36 ± 157.09 949.00 ± 172.78 835.62 ± 128.31 900.63 ± 148.86 1.995 0.120 NS NS NS NS NS NS
Total 3415.29 ± 524.04 3444.89 ± 553.07 3072.52 ± 363.73 3450.67 ± 414.81 3.213 0.027 0.004** NS NS NS NS NS

Note: CT-SCZ clozapine-treated schizophrenia patients, RT-SCZ risperidone-treated schizophrenia patients, NT-SCZ never-treated schizophrenia patients, HCs healthy controls, NS not significant, *, Significant group difference at P < 0.05; **, P < 0.01; ***, P < 0.001